DAX21.206 -0,5%ESt504.935 -0,6%Top 10 Crypto11,33 +4,4%Dow39.142 -1,3%Nas16.286 -0,1%Bitcoin74.684 ±0,0%Euro1,1373 ±0,0%Öl67,85 +2,7%Gold3.328 ±0,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Rheinmetall 703000 Siemens Energy ENER6Y Tesla A1CX3T RENK RENK73 Apple 865985 Amazon 906866 Lufthansa 823212 Mercedes-Benz Group (ex Daimler) 710000 Novo Nordisk A3EU6F Allianz 840400 BASF BASF11 Infineon 623100 Volkswagen (VW) vz. 766403 HENSOLDT HAG000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Nach EZB-Entscheid: DAX geht leichter ins lange Osterwochenende -- Netflix mit Gewinnplus -- EZB senkt Leitzins -- Siemens Energy, TSMC, NVIDIA, ASML, UnitedHealth, Hertz im Fokus
Top News
Diese Aktien empfehlen Experten zu kaufen Diese Aktien empfehlen Experten zu kaufen
Weiterer Antrag auf Dogecoin-ETF eingereicht Weiterer Antrag auf Dogecoin-ETF eingereicht
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
"600% Momentum-Strategie": Aktien hebeln und Gewinne maximieren - sichern Sie sich jetzt das Kennenlernangebot für nur 39 Euro (statt 69 Euro) im Monat!

REGENXBIO Aktie

NeuKaufenVerkaufen
REGENXBIO Aktien-Sparplan
5,20 EUR -0,10 EUR -1,89 %
STU
5,92 USD -0,23 USD -3,75 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.271,43 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA140E0

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS75901B1070

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolRGNX

REGENXBIO Aktien News

DatumMeistgelesen
PR NewswireREGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint
PR NewswireREGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® Trial
PR NewswireREGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024
PR NewswireREGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery
PR NewswireREGENXBIO Announces Presentation at the Hawaiian Eye and Retina 2024 Meeting
PR NewswireREGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE® Trial
PR NewswireREGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial Results
PR NewswireREGENXBIO to Participate in Upcoming Investor Conferences
PR NewswireREGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
PR NewswireREGENXBIO to Host Conference Call on November 8 to Discuss Third Quarter 2023 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting
PR NewswireREGENXBIO to Participate in the Jefferies CNS/Neuro Summit
PR NewswireREGENXBIO Presents Interim Clinical Data from Phase I/II AFFINITY DUCHENNE™ Trial of RGX-202 at 28th Annual International Congress of the World Muscle Society
PR NewswireREGENXBIO Announces Presentations at the 28th Annual Congress of the World Muscle Society
PR NewswireREGENXBIO to Participate in Upcoming Investor Conferences
PR NewswireInitial Clinical Data of First Pediatric CLN2 Patient Dosed with RGX-181 Presented at SSIEM Annual Symposium
PR NewswireREGENXBIO Announces Presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023
PR NewswireREGENXBIO Reports Second Quarter 2023 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO Announces Participation at the 2023 Wedbush PacGrow Healthcare Conference
PR NewswireREGENXBIO to Host Conference Call on August 2 to Discuss Second Quarter 2023 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO Announces Upcoming Presentations at the American Society of Retina Specialists Annual Scientific Meeting
PR NewswireREGENXBIO Highlights AAV Pipeline with Interim Results from Retinal and Duchenne Programs at its Virtual Investor Day on July 11, 2023
PR NewswireREGENXBIO to Host Virtual Investor Day Highlighting AAV Pipeline Programs with Upcoming Interim Trial Updates
PR NewswireREGENXBIO Announces Presentation at the Jefferies Global Healthcare Conference
PR NewswireREGENXBIO Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RGX-121 Gene Therapy for Hunter Syndrome
PR NewswireREGENXBIO Announces Presentation at the Barclays Gene Editing & Therapy Summit 2023
PR NewswireREGENXBIO Announces NAV® Technology Platform Will Support Bespoke Gene Therapy Consortium's First Rare Disease Clinical Portfolio
PR NewswireREGENXBIO to Participate in Upcoming Investor Conferences
PR NewswireREGENXBIO Reports First Quarter 2023 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 26th Annual Meeting
PR NewswireREGENXBIO to Host Conference Call on May 3 to Discuss First Quarter 2023 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO Announces Presentation at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
PR NewswireREGENXBIO Receives FDA Fast Track Designation for RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy
PR NewswireREGENXBIO to Participate in Upcoming Investor Conferences
PR NewswireREGENXBIO Reports Fourth Quarter 2022 and Full-Year 2022 Financial Results and Recent Operational Highlights
PR NewswireAdditional Positive Interim Data from Phase I/II Trial of REGENXBIO'S RGX-111 for the Treatment of Severe MPS I Presented at WORLDSymposium™
PR NewswireAdditional Positive Interim Data from Phase I/II/III CAMPSIITE™ Trial of REGENXBIO's RGX-121 for the Treatment of MPS II (Hunter Syndrome) Presented at 19th Annual WORLDSymposiumTM
PR NewswireREGENXBIO to Host Conference Call on February 28 to Discuss Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO Announces Presentations at the 19th Annual WORLDSymposium™ 2023
Wer­bung

REGENXBIO News

REGENXBIO News: auf dieser Seite finden Sie alle REGENXBIO News und Nachrichten zur REGENXBIO Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch REGENXBIO News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um REGENXBIO News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.